Format

Send to

Choose Destination
Clin Med Insights Case Rep. 2014 Nov 19;7:131-4. doi: 10.4137/CCRep.S16915. eCollection 2014.

Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.

Author information

1
Department of Cardiology, Pacific Heart, Los Angeles, CA, USA and Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Abstract

Coronary artery disease (CAD) and erectile dysfunction (ED) frequently coexist. The introduction of phosphodiesterase type-5 (PDE-5) inhibitors has revolutionized medical management of organic ED; however, in patients with angina pectoris, a common symptom of CAD, coadministration of PDE-5 inhibitors and nitrates has been implicated in CAD-related deaths following sexual activity. The mechanism of action of PDE-5 inhibitors results in a potential cumulative drop in blood pressure (BP); thus, these agents are contraindicated in patients receiving nitrates. Beta-blockers and calcium channel antagonists are considered the mainstays of antianginal therapy, but may not be tolerated by all patients. Ranolazine is an antianginal agent that produces minimal reductions in heart rate and BP. Here we report three cases of men with CAD, chronic angina, and concomitant ED. We describe our treatment approach in these patients, using ranolazine as a potential substitute to nitrate therapy.

KEYWORDS:

arteriosclerosis; erectile dysfunction; myocardial ischemia; phosphodiesterase type-5 inhibitors

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center